WHAT IS CLAIMED IS:

- 1. A method of treating a CCR4-mediated condition or disease in a subject, said method comprising administering to a subject in need of such treatment an effective amount of a compound having the formula:
 - Ar^1-X-Ar^2 (I)

5 wherein

1

2

3

4

6 7

8

9

1


1

1

2

3

- Ar¹ and Ar² are each members independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted fused arylheterocyclic ring systems and substituted or unsubstituted heteroaryl; and X is a linking group selected from the group consisting of -N(R)-, -C(O)S-,
- -CH=CHSO₂- and -SO₂N(R)- wherein R is a member selected from the group consisting of H and substituted or unsubstituted (C₁-C₈)alkyl.
 - 2. A method in accordance with claim 1, wherein X is –NH-.
 - 3. A method in accordance with claim 1, wherein X is -SO₂NH-.
 - 4. A method in accordance with claim 1, wherein Ar¹ and Ar² are each substituted or unsubstituted members independently selected from the group consisting of:



- 5. A method in accordance with claim 2, wherein Ar¹ is substituted heteroaryl and Ar² is substituted or unsubstituted aryl.
- 6. A method in accordance with claim 5, wherein said Ar¹ is a substituted heteroaryl selected from the group consisting of substituted thiazolyl, substituted thienyl, and substituted furanyl.

1	7. A method in accordance with claim 5, wherein said Ar ² is a	
2	substituted or unsubstituted phenyl or a substituted or unsubstituted naphthyl.	
1	8. A method in accordance with claim 3, wherein Ar ² is a phenyl	
2	group having from 1 to 4 substituents independently selected from the group consisting of	
3	halogen, hydroxy, (C ₁ -C ₄)alkyl, (C ₁ -C ₄)alkoxy, (C ₁ -C ₄)alkylthio, (C ₁ -C ₄)haloalkyl, (C ₁ -C ₄)	
4	C ₄)haloalkoxy, nitro, cyano, (C ₁ -C ₄)acyl, amino, (C ₁ -C ₄)alkylamino, and di(C ₁ -C ₄)	
5	C ₄)alkylamino.	
1	9. A method in accordance with claim-8, wherein said phenyl group	
2	has from 1 to 3 substituents independently selected from the group consisting of halogen,	
3	(C ₁ -C ₄)haloalkyl, (C ₁ -C ₄)haloalkoxy, nitro, cyano, and (C ₁ -C ₄)acyl.	
1	10. A method in accordance with claim 3, wherein Ar ¹ is a substituted	
2	or unsubstituted monocyclic or bicyclic heterocycle.	
_		
1	11. A method in accordance with claim 10, wherein said heterocycle is	
2	selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl,	
3	isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxadiazolyl,	
4	purinyl, benzimidazolyl indolyl, isoquinolyl, quinoxalinyl and quinolyl.	
1	12. A method in accordance with claim 11, wherein said heterocycle is	
2	selected from the group consisting of thienyl, thiazolyl and benzoxadiazolyl.	
1	13. A method in accordance with claim 1, wherein said CCR4-	
2	mediated condition or disease is selected from the group consisting of contact	
3	hypersensitivity, atopic dermatitis, allergic airway hypersensitivity, allergic rhinitis,	
4	atherosclerosis, septic shock, angina, myocardial infarction, restenosis,	
5	ischemia/reperfusion injury, multiple sclerosis, rheumatoid arthritis, type I diabetes,	
6	psoriasis, cancer and HIV infection.	
1	14. A method in accordance with claim 1, wherein said CCR4-	
2	mediated condition or disease is psoriasis, contact hypersensitivity or atopic dermatitis.	
1	15. A method in accordance with claim 14, wherein said CCR4-	
2	mediated condition or disease is psoriasis.	

1	16. A method in accordance with claim 14, wherein said CCR4-
2	mediated condition or disease is contact hypersensitivity.
1	17 A mothed in accordance with claim 14 mhomin gold CCD4
1	17. A method in accordance with claim 14, wherein said CCR4-
2	mediated condition or disease is atopic dermatitys.
1	18. A method in accordance with claim 1, wherein said CCR4-
2	mediated condition or disease is a disease of the airway.
1	19. A method in accordance with claim 18, wherein said disease of the
2	airway is selected from the group consisting of allergic asthma and allergic rhinitis.
1	20. A method in accordance with claim 18, wherein said disease of the
2	airway is allergic asthma.
1	21. A method in accordance with claim 1, wherein said CCR4-
1	\wedge , /
2	mediated condition or disease is a disease of innate immunity.
1	A method in accordance with claim 21, wherein said disease of
2	innate immunity is septic shock.
2	minute immunity is septial shock.
1	23 method in accordance with claim 1, wherein said CCR4-
2	mediated condition or/disease is atherosclerosis.
	\mathcal{T}
1	24. / A method in accordance with claim 1, wherein said CCR4-
2	mediated condition or disease is a disease or condition characterized by platelet
3	aggregation or thrombosis.
1	25. A method in accordance with claim 24, wherein said CCR4-
2	mediated disease or condition is selected from the group consisting of angina, myocardial
3	infarction, restenosis, stroke and ischemia/reperfusion injury.
1	/ 26. A method in accordance with claim 1, wherein said CCR4-
2	mediated condition or disease is an allergic condition and said compound is used alone or
3	in combination with at least one therapeutic agent wherein said therapeutic agent is an
4	antihistamine.

1	27. A method in accordance with claim 1, wherein said CCR4-
2	mediated disease or condition is psoriasis and said compound is used alone or in
3	combination with at least one therapeutic agent selected from a corticosteroid, a lubricant,
4	a keratolytic agent, a vitamin D ₃ derivative, PUVA, or anthralin.
1	28. A method in accordance with claim 1, wherein said CCR4-
2	mediated disease or condition is atopic dermatitis and said compound is used alone or in
3	combination with at least one therapeutic agent/selected from a lubricant and
4	corticosteroid.
1	29. A method in accordance with claim 1, wherein said CCR4-
2	mediated condition or disease is asthma and said compound is used alone or in
3	combination with at least one therapeut agent selected from a ß2-agonist and a
4	corticosteroid.
1	30. A method in accordance with claim 1, wherein said compound
2	interferes with the interaction between CCR4 and a ligand.
1 2	31. A method in accordance with claim 1, wherein said administration is oral or intravenous.
1	32. Amethod in accordance with claim 1, wherein said subject is
2	selected from the group consisting of human, rat, dog, cow, horse, and mouse.
1	33. Amethod in accordance with claim 1, wherein said subject is human.
1	34. A method in accordance with claim 1, wherein said compound is
2	selected from the group consisting of

35. A method in accordance with claim 1, wherein said CCR4mediated disease or condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, type I diabetes, psoriasis, cancer and HIV infection; Ar¹ is a substituted heterocycle; X is -SO₂NH-; and Ar² is a substituted phenyl.

- 36. A method in accordance with claim 1, wherein said CCR4-mediated disease or condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, type I diabetes, psoriasis, cancer and HIV infection; Ar¹ is a substituted heterocycle; X is MH-; and Ar² is naphthyl.
- 37. A pharmal eutical composition for the treatment of a CCR4-mediated disease or condition, said composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound which inhibits the binding of MDC or TARC to CCR4/said compound having the formula:

$$Ar^1-X-Ar^2$$
 (I)

- Ar¹ and Ar² are each members independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted fused arylheter cyclic ring systems and substituted or unsubstituted heteroaryl; and X is a linking group selected from the group consisting of –N(R)-, -C(O)S-, -CH=CHSO₂- and –SO₂N(R)- wherein R is a member selected from the group consisting of H and substituted or unsubstituted (C₁-C₈)alkyl.
- 38. A composition of claim 37, wherein X is –NH-.
 - β 9. A composition of claim 37, wherein X is $-SO_2NH$.


1

2

1

2

40. A composition of claim 37, wherein Ar¹ and Ar² are each
substituted or unsubstituted members independently selected from the group consisting
of:



1 41. A composition of claim 37, wherein Ar¹ is substituted heteroaryl 2 and Ar² is substituted or unsubstituted aryl.

- 42. A composition of claim 41, wherein said Ar¹ is a substituted heteroaryl selected from the group consisting of substituted thiazolyl, substituted thienyl, and substituted furanyl.
- 43. A composition of claim 41, wherein said Ar² is a substituted or unsubstituted phenyl or a substituted or unsubstituted naphthyl.
- 1 44. A composition of claim 41, wherein Ar² is a phenyl group having 2 from 1 to 4 substituents independently selected from the group consisting of halogen,
- 3 hydroxy, (C_1-C_4) alkyl, (C_1-C_4) alkoxy, (C_1-C_4) alkylthio, (C_1-C_4) haloalkyl, (C_1-C_4)
- 4 C_4)haloalkoxy, nitro, cyan ϕ , (C_1 - C_4)acyl, amino, (C_1 - C_4)alkylamino, and di(C_1 -
- 5 C₄)alkylamino.
- 1 45. A composition of claim 44, wherein said phenyl group has from 1
- 2 to 3 substituents independently selected from the group consisting of halogen, (C₁-
- 3 C_4)haloalkyl, (C_1-C_4) haloalkoxy, nitro, cyano, and (C_1-C_4) acyl.
- 1 46. A composition of claim 37, wherein Ar¹ is a substituted or unsubstituted monocyclic or bicyclic heterocycle.
- 1 47. A composition of claim 46, wherein said heterocycle is selected 2 from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl,

1

2

1

2

1

2

- isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxadiazolyl, purinyl, benzimidazolyl, indolyl, isoquinolyl, quinoxalinyl and quinolyl.
- 1 48. A composition of claim 47, wherein said heterocycle is selected 2 from the group consisting of thienyl, thiazolyl and benzoxadiazolyl.
- 1 49. A composition of claim 37, wherein said compound is selected
 2 from the group consisting of

$$F_{3}$$
 F_{3} F_{3

- 50. A method for modulating CCR4 function in a cell, comprising contacting said cell with a CCR4-modulating amount of a composition of claim 37.
- 51. A method for modulating CCR4 function, in which said cell is contacted with a CCR4 protein with a therapeutically effective amount of the composition of claim 37.
 - 52. compound of formula (I):

$$Z \xrightarrow{\mathbb{Z}^{1}} \mathbb{R}^{1}$$
 \mathbb{R}^{2}

4 or a pharmaceutically acceptable salt thereof, wherein

W is selected from aryl, heteroaryl, (C₁-C₈)alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl;


7 X is selected from N(R⁵), S, O, C(R³)=C(R⁴), N=C(R⁴) and, optionally, when Z is N, X can be $C(R^6)(R^7)$;

9	Y is selected from a bond, N(R ⁵), N(R ⁵)-(C ₁ -C ₈)alkylene, O, S and S(O) _n , wherein
10	the integer n is 1 or 2;
11	Z is selected from N and C(R ⁸);
12	R ¹ and R ² are independently selected from H, halogen, CN, CO ₂ R', CONR'R",
13	(C_1-C_8) alkyl, heteroalkyl, aryl, heteroaryl, $N(R^9)(R^7)$, OR^9 and optionally,
14	R ¹ and R ² combine to form a 5- to 8-membered ring containing from 0 to 3
15	heteroatoms selected from N, O and S, wherein R' and R" are
16	independently selected from H, (C ₁ -C ₈)alkyl and aryl, and when R' and R"
17	are attached to nitrogen atom, they may be combined with the nitrogen
18	atom to form a 5-, 6-, or 7-membered ring;
19	R ³ , R ⁴ and R ⁸ are independently selected from H, halogen, CN, OH, (C ₁ -C ₈) alkyl,
20	heteroalkyl, aryl, heteroaryl, $O(C_1-C_9)$ alkyl, $N(R^6)(R^7)$ and OR^9 ;
₫ 21	R^5 is selected from H, (C_1-C_8) alkyl, heteroalkyl, aryl and heteroaryl;
22 23 11 24	R^6 and R^7 are independently selected from H, (C ₁ -C ₈)alkyl, heteroalkyl, aryl and
្នា 23	heteroaryl; and
7 24	R^9 is selected from (C_1-C_8) alkyl, heteroalkyl and haloalkyl;
ជា ជា 25	with the provisos that \mathbb{R}^2 is other than \mathbb{R} when \mathbb{W} is unsubstituted phenyl, \mathbb{X} is \mathbb{S} ,
st 26	Y is NH, Z is N and \mathbb{R}^1 is (C_1 / C_8) alkyl; and \mathbb{R}^1 other than phenyl, when W is phenyl or
2 7	unsubstituted naphthyl, X is \$, Y is NH, and Z is N.
	53. A compound of claim 52, wherein Z is N.
1	53. A compound of claim 52, wherein Z is N.
1	54. A compound of claim 52, wherein X is S.
•	
1	55. A compound of claim 52, wherein Y is N(R ⁵).
1	56. A compound of claim 52, wherein Z is N, X is S and Y is N(R ⁵).
1	57. A compound of claim 52, wherein W is aryl or heteroaryl.
1	58. A compound of claim 57, wherein W is substituted or unsubstituted
2	phenyl or naphthyl.
1	59. A/compound of claim 57, wherein W is substituted or unsubstituted
2	pyridyl or quinolyl.

1	60 .	A compound of claim 52, wherein R ¹ and R ² are each
2	independently selecte	ed from H and (C ₁ -C ₈)alkyl.
_	macpondoning bolloots	
.1	61.	A compound of claim 52, wherein R ¹ and R ² are combined to form
2	a fused 6-membered	aryl or heteroaryl ring.
1	62 .	A compound of claim \$2, wherein Z is N, X is S, Y is N(R ⁵) and
2	R ¹ and R ² are each in	dependently selected from H and (C1-C8)alkyl.
1	63 .	A compound of claim 52, wherein Z is N, X is S, Y is N(R ⁵) and
2		ned to form a fused 6-membered aryl or heteroaryl ring.
2	R and R are comon	lot to form a tused 9-monocrea aryr or necessary rang.
1	64.	A compound of claim 52, said compound being selected from the
2	group consisting of:	

1

Me ←Me Me Me , ←Me Мe 2 12 CI-Me ←Me Me Me Ме Me ←Me Me Me ←Me Me -Me Мe Мe Ìе 10 Me ←Me Me Me ←Me Me 5 19 13 Me Me ←Me Me Ме Me Me Ме 6 Me Me ←Me Me and 20 A compound of claim 52, said compound being selected from the 65/. group consisting of:



66. A compound of claim 52, wherein

W is selected from substituted phenyl, substituted or unsubstituted naphthyl, pyridyl, quinolyl, (C₁-C₈)alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl;

X is selected from $N(R^5)$, S, O, $C(R^3)=C(R^4)$, $N=C(R^4)$ and, optionally, when Z is N, X can be $C(R^6)(R^7)$;

Y is selected from a bond, N(R⁵), N(R⁵)-(C₁-C₈)alkylene, O, S and S(O)_n, wherein the integer n is 1 or 2;

Z is selected from N and $\mathcal{C}(\mathbb{R}^8)$;

R¹ and R² are independently selected from H, halogen, CN, CO₂R', CONR'R", (C₁-C₈)alkyl, heteroalkyl, aryl, heteroaryl, N(R⁶)(R⁷), OR⁹ and optionally, R¹ and R² combine to form a 5- to 8-membered ring containing from 0 to 3 heteroatoms selected from N, O and S, wherein R' and R" are independently selected from H, (C₁-C₈)alkyl and aryl, and when R' and R" are attached to a nitrogen atom, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring;

R³, R⁴ and R⁸ are independently selected from H, halogen, CN, OH, (C₁-C₈)alkyl, heteroaryl, O(C₁-C₈)alkyl, N(R⁶)(R⁷) and OR⁹;

 R^5 is selected from H/, (C_1-C_8) alkyl, heteroalkyl, aryl and heteroaryl;

R⁶ and R⁷ are independently selected from H, (C₁-C₈)alkyl, heteroalkyl, aryl and heteroaryl; and

 R^9 is selected from (C_1-C_8) alkyl, heteroalkyl and haloalkyl.

67. A compound of claim 66, wherein Z is N.

1	68. A compound of claim 66, wherein X is S.
1	69. A compound of claim 66, wherein Y is N(R ⁵).
1	70. A compound of claim 66, wherein Z is N/X is S and Y is $N(R^5)$.
1	71. A compound of claim 66, wherein W is substituted phenyl or
2	substituted or unsubstituted naphthyl.
1	72. A compound of claim 66, wherein W is substituted or unsubstituted
2	pyridyl or substituted or unsubstituted quinolyl.
1	73. A compound of claim $\underline{66}$, wherein R^1 and R^2 are independently
2	selected from the group consisting of H and (C ₁ -C ₂)alkyl.
1	74. A compound of claim 66 , wherein R^1 and R^2 are combined to form
2	a fused 6-membered aryl or heteroary ring.
_	
1	75. A compound of claim 66, wherein W is substituted phenyl or
2	substituted or unsubstituted naphthyl, Z is N, X is S, Y is $N(R^5)$, and R^1 and R^2 are
3	independently selected from the group consisting of H and (C ₁ -C ₈)alkyl.
1	76. A compound of claim 66, wherein W is substituted phenyl or
2	substituted or unsubstituted naphthyl, Z is N, X is S, Y is N(R^5), and R^1 and R^2 are
3	combined to form a fused 6-membered aryl or heteroaryl ring.
	desines to resin a radio e monte et a ary or noticeally range.
1	77. A compound of claim 66, wherein W is substituted or unsubstituted
2	pyridyl or substituted or unsubstituted quinolyl, Z is N, X is S, Y is N(R ⁵), and R ¹ and R ²
3	are independently selected from the group consisting of H and (C ₁ -C ₈)alkyl.
1	78. A compound of claim 66, wherein W is substituted or unsubstituted
2	pyridyl or substituted or unsubstituted quinolyl, Z is N, X is S, Y is N(R ⁵), and R ¹ and R ²
3	are combined to form a fused 6-membered aryl or heteroaryl ring.
1	79. A pharmaceutical composition comprising a pharmaceutically
2	acceptable carrier and a compound of formula (I):
	$/$ \mathbb{R}^1
	/ <u>Z</u>

4	I
5	or a pharmaceutically acceptable salt thereof, wherein
6	W is selected from aryl, heteroaryl, (C ₁ -C ₈)alkyl, heteroalkyl, cycloalkyl and
7	heterocycloalkyl;
8	X is selected from $N(R^5)$, S, O, $C(R^3)=C(R^4)$, $N=C(R^4)$ and, optionally, when Z is
9	N, X can be $C(R^6)(R^7)$;
10	Y is selected from a bond, N(R ⁵), N(R ⁵)-(C ₁ -C ₈)alkylene, O, S and S(O) _n , wherein
11	the integer n is 1 or 2;
12	Z is selected from N and $C(R^8)$;
13	R ¹ and R ² are independently selected from H, halogen, CN, CO ₂ R', CONR'R",
14	(C ₁ -C ₈)alkyl, heteroalkyl, aryl, heteroaryl, N(R ⁶)(R ⁷), OR ⁹ and optionally,
15	R ¹ and R ² combine to form a 5-/10 8-membered ring containing from 0 to 3
16	heteroatoms selected from N, O and S, wherein R' and R" are
17	independently selected from H, (C ₁ -C ₈)alkyl and aryl, and when R' and R"
18	are attached to nitrogen atom, they may be combined with the nitrogen
19	atom to form a/5-, 6-, of -membered ring;
20	R ³ , R ⁴ and R ⁸ are independently selected from H, halogen, CN, OH, (C ₁ -C ₈)alkyl,
21	heteroalkyl, aryl, heteroaryl, $O(C_1-C_8)$ alkyl, $N(R^6)(R^7)$ and OR^9 ;
22	R ⁵ is selected from H, (C ₁ -C ₈) alkyl, heteroalkyl, aryl and heteroaryl;
23	R^6 and R^7 are independently selected from H, (C_1-C_8) alkyl, heteroalkyl, aryl and
24	heteroaryl; and
25	R^9 is selected from C_1 - C_8) alkyl, heteroalkyl and haloalkyl.
1	80. A phethod for treating a CCR4-mediated condition in a subject, said
2	method comprising administering to a subject in need of such treatment an effective

$$V = X \times \mathbb{R}^{1}$$
 $V = X \times \mathbb{R}^{2}$

or a pharmaceutically acceptable salt thereof, wherein

amount of a compound of of formula (I):


W is selected from aryl, heteroaryl, (C₁-C₈)alkyl, heteroalkyl, cycloalkyl and heterocycloalkyl;

X is selected from $N(R^5)$, S, O, $C(R^3)=C(R^4)$, $N=C(R^4)$ and, optionally, when Z is N, X can be $C(R^6)(R^7)$;


3

Y is selected from a bond, N(R⁵), N(R⁵)-(C₁-C₈)alkylene, O, S and S(O)_n, wherein 11 12 the integer n is 1 or 2; Z is selected from N and $C(R^8)$; 13 R^1 and R^2 are independently selected from H, halogen, CN, CQ_2R' , CONR'R", 14 (C_1-C_8) alkyl, heteroalkyl, aryl, heteroaryl, $N(R^6)(R^7)$, OR^9 and optionally, 15 . R¹ and R² combine to form a 5- to 8-membered ring containing from 0 to 3 16 17 heteroatoms selected from N, O and S, wherein R' and R" are independently selected from H, (C₁-C₈)alkyl and aryl, and when R' and R" 18 19 are attached to nitrogen atom, they may be combined with the nitrogen 20 atom to form a 5-, 6-, or 7-membered rings R³, R⁴ and R⁸ are independently selected from H, halogen, CN, OH, (C₁-C₈)alkyl, 21 heteroalkyl, aryl, heteroaryl, O(C₁-C₈)alkyl, N(R⁶)(R⁷) and OR⁹; 22 R⁵ is selected from H, (C₁-C₈)alkyl, heteroalkyl, aryl and heteroaryl; 23 R⁶ and R⁷ are independently/selected from/H, (C₁-C₈)alkyl, heteroalkyl, aryl and 24 25 heteroaryl; and 26 R⁹ is selected from (C₁-C₈)alkyl, heter alkyl and haloalkyl. 1

81. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected from the group consisting of:



- A method for treating a CCK4-mediated condition in a subject, said 83.
- method comprising administering to a subject in need of such treatment an effective 2
- 3 amount of a compound selected from the group consisting of:



selected from the group consisting of: